Xenetic Biosciences Net Worth
Xenetic Biosciences Net Worth Breakdown | XBIO |
Xenetic Biosciences Net Worth Analysis
Xenetic Biosciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Xenetic Biosciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Xenetic Biosciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Xenetic Biosciences' net worth analysis. One common approach is to calculate Xenetic Biosciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Xenetic Biosciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Xenetic Biosciences' net worth. This approach calculates the present value of Xenetic Biosciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Xenetic Biosciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Xenetic Biosciences' net worth. This involves comparing Xenetic Biosciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Xenetic Biosciences' net worth relative to its peers.
Enterprise Value |
|
To determine if Xenetic Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Xenetic Biosciences' net worth research are outlined below:
| Xenetic Biosciences had very high historical volatility over the last 90 days | |
| Xenetic Biosciences has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.54 M. Net Loss for the year was (4.13 M) with profit before overhead, payroll, taxes, and interest of 1.16 M. | |
| Xenetic Biosciences currently holds about 14.93 M in cash with (4.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.04. | |
| Roughly 19.0% of the company outstanding shares are owned by insiders | |
| Latest headline from finance.yahoo.com: Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis |
Xenetic Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Xenetic Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Xenetic Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Xenetic Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Xenetic Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Xenetic Biosciences backward and forwards among themselves. Xenetic Biosciences' institutional investor refers to the entity that pools money to purchase Xenetic Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Sachetta Llc | 2024-09-30 | 17.4 K | Renaissance Technologies Corp | 2024-09-30 | 15.8 K | Geode Capital Management, Llc | 2024-06-30 | 12 K | Jtc Employer Solutions Trustee Ltd | 2024-09-30 | 2.7 K | Ubs Group Ag | 2024-06-30 | 182 | Bank Of America Corp | 2024-06-30 | 11.0 | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Tower Research Capital Llc | 2024-06-30 | 0.0 | Steward Partners Investment Advisory, Llc | 2024-06-30 | 0.0 |
Follow Xenetic Biosciences' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.19 M.Market Cap |
|
Project Xenetic Biosciences' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.39) | (0.41) | |
| Return On Capital Employed | (0.46) | (0.48) | |
| Return On Assets | (0.39) | (0.41) | |
| Return On Equity | (0.42) | (0.44) |
When accessing Xenetic Biosciences' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Xenetic Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Xenetic Biosciences' profitability and make more informed investment decisions.
Evaluate Xenetic Biosciences' management efficiency
Xenetic Biosciences has return on total asset (ROA) of (0.2874) % which means that it has lost $0.2874 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4861) %, meaning that it created substantial loss on money invested by shareholders. Xenetic Biosciences' management efficiency ratios could be used to measure how well Xenetic Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Tangible Assets is likely to drop to -0.41. In addition to that, Return On Capital Employed is likely to drop to -0.48. At this time, Xenetic Biosciences' Total Assets are very stable compared to the past year. As of the 22nd of November 2024, Other Current Assets is likely to grow to about 617.8 K, while Non Current Assets Total are likely to drop about 967.4 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 6.41 | 6.09 | |
| Tangible Book Value Per Share | 6.41 | 6.09 | |
| Enterprise Value Over EBITDA | 0.82 | 0.86 | |
| Price Book Value Ratio | 0.54 | 0.50 | |
| Enterprise Value Multiple | 0.82 | 0.86 | |
| Price Fair Value | 0.54 | 0.50 | |
| Enterprise Value | -3.7 M | -3.5 M |
The operational strategies employed by Xenetic Biosciences management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Enterprise Value Revenue 0.1167 | Revenue 2.5 M | Quarterly Revenue Growth 0.116 | Revenue Per Share 1.638 | Return On Equity (0.49) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Xenetic Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Xenetic Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Xenetic Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Xenetic Biosciences Corporate Filings
8K | 13th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 12th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 31st of October 2024 Other Reports | ViewVerify | |
| 21st of October 2024 Other Reports | ViewVerify |
Xenetic Biosciences Earnings per Share Projection vs Actual
Xenetic Biosciences Corporate Executives
Elected by the shareholders, the Xenetic Biosciences' board of directors comprises two types of representatives: Xenetic Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xenetic. The board's role is to monitor Xenetic Biosciences' management team and ensure that shareholders' interests are well served. Xenetic Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xenetic Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Parslow | CFO, Principal Accounting Officer, Principal Financial Officer | Profile |
Already Invested in Xenetic Biosciences?
The danger of trading Xenetic Biosciences is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Xenetic Biosciences is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Xenetic Biosciences. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Xenetic Biosciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Xenetic Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Xenetic Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xenetic Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xenetic Biosciences Stock: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xenetic Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Xenetic Stock, please use our How to Invest in Xenetic Biosciences guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xenetic Biosciences. If investors know Xenetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xenetic Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.66) | Revenue Per Share 1.638 | Quarterly Revenue Growth 0.116 | Return On Assets (0.29) | Return On Equity (0.49) |
The market value of Xenetic Biosciences is measured differently than its book value, which is the value of Xenetic that is recorded on the company's balance sheet. Investors also form their own opinion of Xenetic Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Xenetic Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xenetic Biosciences' market value can be influenced by many factors that don't directly affect Xenetic Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xenetic Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenetic Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xenetic Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.